论文部分内容阅读
本文作者用麦角隐亭治疗106例晚期巴金森氏病患者.对其中的28例进行了长期的随访.这28例患者的平均年龄为62.2岁,平均病程为10.2年,麦角隐亭平均使用时间是2.8年(至少2年).在使用麦角隐亭前,他们均接受过左旋多巴(单独或与carbidopa合并应用)治疗,治疗时间平均为7.4年,其中大部份患者曾经是有效的.然而,随着治疗时间的延长,病情又开始出现恶化,且有21例(75%)出现“开关”现象.此时增加左旋多巴的剂量引起付作用加重(不自主运动和精神症状);而减少左旋多巴的剂量,却又造成巴金森氏病的恶化.经过全面的检查和征得患者同意后,应用麦角隐亭,开始剂量为5-10mg/日,住院患者每天增加5-10mg,门诊患者每周日量增加5-10mg,直至出现毒性作用(平均剂量56mg/日).开始时,不减少左旋多巴的剂量,但是以后由于付作用增加,将左旋多巴减量,原来
The authors used ergocryptine to treat 106 patients with advanced Parkinson’s disease and 28 of them were followed up for a long period of time.The average age of these 28 patients was 62.2 years with an average duration of 10.2 years and the average duration of use of ergocryptine Was 2.8 years (at least 2 years). Before using ergocalciferin, they all received levodopa (either alone or in combination with carbidopa) for an average of 7.4 years, most of whom had been active. However, as the duration of treatment increased, the disease started to deteriorate again, with 21 (75%) “switching.” Increasing the dose of levodopa at this time caused an increase in pay (involuntary movements and psychiatric symptoms ); And reduce the dose of levodopa, but also cause deterioration of Parkinson’s disease.After a comprehensive examination and consent of patients, the application of ergocryptine, the initial dose of 5-10mg / day, hospital patients increased by 5 -10mg, outpatients per week increase in the amount of 5-10mg, until toxic effects (average dose 56mg / day.) Initially, do not reduce the dose of levodopa, but later due to pay increased, the levodopa reduction, the original